Protagonist Therapeutics (PTGX) has drawn fresh attention after reporting second quarter 2026 results that shifted from a net loss to net income of US$162.85 million, with earnings emerging from continuing operations.

The sharp move from losses to net income has coincided with strong share price momentum for Protagonist Therapeutics, with a 90 day share price return of 40.94% and a year to date share price return of 67.32%. Over a longer horizon, total shareholder return is very large at about 7x over three years, pointing to sustained enthusiasm around the story behind the current US$145.87 share price.

If this kind of acceleration in sentiment catches your eye, it can be useful to look at other healthcare stocks harnessing similar themes in AI and data driven drug development through the 43 healthcare AI stocks.

Protagonist Therapeutics now has profits on the board and a share price that has surged with it. The real test for investors comes next. Does the current valuation still leave room for attractive long term returns?

Price-to-Earnings of 113.8x: Is it justified?

On simple headline metrics, Protagonist Therapeutics trades on a P/E of 113.8x, which looks rich against its latest close at $145.87 and its recent move into sustained profitability.

The P/E multiple compares the current share price with earnings per share. For a company like Protagonist Therapeutics that has only recently turned profitable and is still investing heavily in its pipeline, this ratio effectively reflects what the market is willing to pay today for each dollar of current earnings.

High P/E ratios are often associated with strong expectations for future profit growth. In this case, earnings are forecast to grow 28.6% per year, which is faster than the broader US market forecast of 16.7% per year. That profile can help explain why investors are paying a higher multiple on today’s earnings even though current Return on Equity is 9.9% and forecast to remain low at 2.4% in three years. This suggests that expectations are firmly anchored on future earnings power rather than present day profitability metrics.

The comparison with peers is stark. The US Biotechs industry trades on an average P/E of 17.3x, while Protagonist Therapeutics sits at 113.8x. Against the peer average of 84.8x and an estimated fair P/E of 31.8x, the current multiple is much higher and implies the market price could compress toward that fair ratio if sentiment or growth expectations cool.

Result: Price-to-Earnings of 113.8x (OVERVALUED)

However, Protagonist Therapeutics still faces key risks, including clinical or regulatory setbacks in its pipeline, as well as any cooling of sentiment toward high P/E biotech stocks.

Another view on Protagonist Therapeutics valuation

The high P/E paints Protagonist Therapeutics as expensive, but the SWS DCF model points in the opposite direction. On this view, the current $145.87 share price is about 73.8% below an estimated future cash flow value of $557.26, which screens as materially undervalued. Which signal do you trust more when the story and the numbers disagree?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Protagonist Therapeutics already running high, now is the time to look through the numbers yourself and stress test the story. To see what the market currently views as the upside, review the 3 key rewards

Looking for more Protagonist Therapeutics sized ideas?

If Protagonist Therapeutics has sharpened your focus on stock selection, do not stop here. Use these idea lists to spot opportunities others are still overlooking.

• Target dependable income by scanning companies that appear in the 8 dividend fortresses and see which yields might fit your portfolio goals.
• Hunt for potential mispricing by reviewing the screener containing 21 high quality undiscovered gems where strong fundamentals are not yet widely recognised.
• Prioritise resilience by focusing on companies featured in the 83 resilient stocks with low risk scores and see which stocks score well on stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.